Novartis to bolster its oncology portfolio with acquisition of MorphoSys

Novartis AG on Monday announced it has agreed to buy German biopharmaceutical company MorphoSys AG for 2.7 billion euros ($ 2.9 billion). Under the deal, Switzerland-based Novartis would acquire pelabresib, a potential treatment for myelofibrosis, and the anti-tumor drug tulmimetostat.  “With the planned acquisition of MorphoSys, we aim to further strengthen our leading pipeline and […]

Continue Reading

After frustrating FAFSA delays, feds will provide personnel and funding to assist colleges

The Department of Education is beefing up resources at certain colleges and financial-aid organizations after weeks of complaints from students, college counselors, schools and congressional Republicans over the delayed launch of the new FAFSA form.  Secretary of Education Miguel Cardona said Monday his agency would deploy federal financial-aid personnel to under-resourced colleges, including Historically Black […]

Continue Reading

Fed’s Powell shouldn’t ‘waste’ interest-rate cuts and risk resurgence of inflation, says ‘The Big Short’ investor Steve Eisman

“‘They’ve [The Fed] engineered what looks to be a soft landing, inflation is coming down, the economy is still strong. Why would you waste rate cuts now and risk a resurgence of inflation when all you really need to do is declare victory?‘” — Steve Eisman, senior portfolio manager at Neuberger Berman Group. Steve Eisman, […]

Continue Reading

If Trump’s pro-business agenda was thwarted by bureaucrats, his allies have a plan to avoid a repeat

Donald Trump’s major policy initiatives during his term as president were a massive tax cut and a governmentwide effort to cut regulations that he argued cost the U.S. economy trillions of dollars and “devastated entire industries.” Lax oversight of environmental, safety and labor standards, to name three categories, represented a policy pivot that united Trump […]

Continue Reading